Who makes TDM-105795, 0.02%?

TDM-105795, 0.02% is developed by Technoderma Medicines Inc..

What development phase is TDM-105795, 0.02% in?

TDM-105795, 0.02% is in Phase 2.

Last reviewed 2026-04-19 · How we verify

TDM-105795, 0.02%

Technoderma Medicines Inc. · Phase 2 active Small molecule

At a glance

Generic name	TDM-105795, 0.02%
Sponsor	Technoderma Medicines Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia (PHASE2)
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TDM-105795, 0.02% CI brief — competitive landscape report
TDM-105795, 0.02% updates RSS · CI watch RSS
Technoderma Medicines Inc. portfolio CI